Insmed Inc
NASDAQ:INSM

Watchlist Manager
Insmed Inc Logo
Insmed Inc
NASDAQ:INSM
Watchlist
Price: 73.15 USD -0.89% Market Closed
Market Cap: 13.1B USD
Have any thoughts about
Insmed Inc?
Write Note

Insmed Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Insmed Inc
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Insmed Inc
NASDAQ:INSM
Income from Continuing Operations
-$802.7m
CAGR 3-Years
-29%
CAGR 5-Years
-20%
CAGR 10-Years
-27%
Abbvie Inc
NYSE:ABBV
Income from Continuing Operations
$5.1B
CAGR 3-Years
-12%
CAGR 5-Years
9%
CAGR 10-Years
3%
Gilead Sciences Inc
NASDAQ:GILD
Income from Continuing Operations
$113m
CAGR 3-Years
-75%
CAGR 5-Years
-47%
CAGR 10-Years
-36%
Amgen Inc
NASDAQ:AMGN
Income from Continuing Operations
$4.2B
CAGR 3-Years
-9%
CAGR 5-Years
-12%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Income from Continuing Operations
-$479.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
2%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Income from Continuing Operations
$4.7B
CAGR 3-Years
-13%
CAGR 5-Years
17%
CAGR 10-Years
30%
No Stocks Found

Insmed Inc
Glance View

Market Cap
12.2B USD
Industry
Biotechnology

Insmed Inc. is a biopharmaceutical company on a mission to transform the lives of patients with severe and rare diseases, particularly those related to lung and infectious conditions. Founded in 1988, Insmed has carved out a niche in the biotechnology landscape with its innovative approach to drug development. The company's flagship product, Arikayce, has gained approval for the treatment of nontuberculous mycobacterial (NTM) lung infections, demonstrating its commitment to addressing unmet medical needs. With a robust pipeline of therapeutic candidates focusing on rare diseases, Insmed is not just another player in the biopharma space; it is dedicated to solving complex health challenges where conventional therapies have fallen short. Investors should take note of Insmed’s strategic direction and strong market position. The company is actively expanding its reach through ongoing clinical trials for its next generation therapies, which aim to target diseases with limited treatment options. With a solid financial foundation and partnerships that bolster its research capabilities, Insmed is poised for growth. As healthcare organizations increasingly prioritize personalized medicine and innovative treatments, Insmed's willingness to tackle rare conditions places it on a promising trajectory. For investors, this represents an opportunity not just in terms of potential financial returns, but also in contributing to advancements in healthcare that can have a meaningful impact on patients' lives.

INSM Intrinsic Value
55.7 USD
Overvaluation 24%
Intrinsic Value
Price

See Also

What is Insmed Inc's Income from Continuing Operations?
Income from Continuing Operations
-802.7m USD

Based on the financial report for Jun 30, 2024, Insmed Inc's Income from Continuing Operations amounts to -802.7m USD.

What is Insmed Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-27%

Over the last year, the Income from Continuing Operations growth was -15%. The average annual Income from Continuing Operations growth rates for Insmed Inc have been -29% over the past three years , -20% over the past five years , and -27% over the past ten years .

Back to Top